There are 2137 resources available
1620O - Phase I study of TK216, a novel anti-ETS agent for Ewing sarcoma
Presenter: Joseph Ludwig
Session: Proffered Paper - Sarcoma
Resources:
Abstract
Slides
Webcast
LBA72 - Assessment of clinical and laboratory prognostic factors in patients with cancer and SARS-CoV-2 infection: The COVID-19 and Cancer Consortium (CCC19)
Presenter: Petros Grivas
Session: Proffered Paper - SARS-CoV-2 and cancer 2
Resources:
Abstract
Slides
Webcast
LBA73 - The ORF1ab of SARS-CoV-2 encodes an immunodominant epitope restricted by HLA-A*01:01
Presenter: Pia Kvistborg
Session: Proffered Paper - SARS-CoV-2 and cancer 2
Resources:
Abstract
Slides
Webcast
LBA74 - Disparities in cancer during the COVID-19 pandemic: COVID-19 and cancer outcomes study (CCOS)
Presenter: Deborah Doroshow
Session: Proffered Paper - SARS-CoV-2 and cancer 2
Resources:
Abstract
Slides
Webcast
LBA75 - Defining COVID-19 outcomes in thoracic cancer patients: TERAVOLT (Thoracic cancERs international coVid 19 cOLlaboraTion)
Presenter: Javier Baena Espinar
Session: Proffered Paper - SARS-CoV-2 and cancer 2
Resources:
Abstract
Slides
Webcast
527O - CC-90010, a reversible, oral bromodomain and extra-terminal (BET) inhibitor in patients (Pts) with advanced solid tumours (STs) and relapsed/refractory (R/R) non-Hodgkin lymphoma: Updated results of a phase I study
Presenter: Victor Moreno Garcia
Session: Proffered Paper - Developmental therapeutics
Resources:
Abstract
Slides
Webcast
528O - CC-90011 in patients (Pts) with advanced solid tumours (STs) and relapsed/refractory non-Hodgkin lymphoma (R/R NHL): Updated results of a phase I study
Presenter: Antoine Hollebecque
Session: Proffered Paper - Developmental therapeutics
Resources:
Abstract
Slides
Webcast
524O - Initial results of a phase I study of MK-4830, a first-in-class anti–immunoglobulin-like transcript 4 (ILT4) myeloid-specific antibody in patients (pts) with advanced solid tumours
Presenter: Lillian Siu
Session: Proffered Paper - Developmental therapeutics
Resources:
Abstract
Slides
Webcast
525O - A phase I dose escalation study of PRS-343, a HER2/4-1BB bispecific molecule, in patients with HER2-positive malignancies
Presenter: Geoffrey Ku
Session: Proffered Paper - Developmental therapeutics
Resources:
Abstract
Slides
Webcast
526O - High activity of nivolumab in patients with pathogenic exonucleasic domain POLE (edPOLE) mutated Mismatch Repair proficient (MMRp) advanced tumours
Presenter: Benoit Rousseau
Session: Proffered Paper - Developmental therapeutics
Resources:
Abstract
Slides
Webcast